SciSparc Ltd. (SPRC) – Market Activity and Corporate Developments
Premarket Movements
On Wednesday, September 17, 2025, pre‑market trading on Nasdaq showed SciSparc Ltd. (ticker SPRC) among the top gainers. At 7:55 a.m. ET, the stock was trading higher, indicating early momentum that many traders interpreted as a potential breakout for the regular trading session. The pre‑market rally was reported by Finanznachrichten.de and TipRanks as part of a broader set of stocks experiencing notable early price activity.
Merger‑Related Rally
The most significant catalyst for the 130 % price surge was an update concerning SciSparc’s planned merger with AutoMax Motors, an Israeli car importer. AutoMax filed a motion to delay the merger until September 30, 2025, or until a Jerusalem District Court ruling indicates that the merger conditions cannot be met. The announcement prompted a rapid and substantial rise in the SciSparc share price.
TipRanks highlighted the rally, noting that the stock’s increase of +2.22 % on the day was directly tied to the merger delay filing. SeekingAlpha and Feedburner reports corroborated the move, emphasizing that the market viewed the delay as a positive development for SciSparc, potentially allowing the company to negotiate more favorable terms or seek alternative partnership opportunities.
Subsequent Developments
On September 18, the Thai Stock Exchange (SET) announced that a derivative warrant (symbol SPRC01C2602A) will be listed on September 19, 2025. The warrant, issued by Bualuang Securities Public Company Limited, is a call warrant on Star Petroleum Refining Public Company Limited. While the warrant is unrelated to SciSparc’s core business, the listing indicates that the SET is adding securities with the SPRC symbol to its trading roster, which may introduce additional liquidity options for investors holding SciSparc shares.
Company Overview
SciSparc Ltd. is a health‑care biotechnology firm headquartered in Tel Aviv, Israel. The company focuses on developing cannabinoid‑based technologies for central nervous system disorders. It trades on Nasdaq in U.S. dollars, with a market capitalization of approximately $2.3 million. As of September 16, 2025, the stock closed at $4.47, with a 52‑week range between $1.75 and $37.59.
Market Implications
The merger‑related news and subsequent market rally suggest that investors view the partnership with AutoMax Motors as a strategic advantage for SciSparc’s growth. The pre‑market activity indicates strong early interest, while the rapid price increase confirms that the market is pricing in potential benefits from the merger or alternative strategic moves.
Investors monitoring SciSparc should track the final outcome of the merger proceedings scheduled for late September and any further corporate announcements that may influence the company’s valuation.